GLS and neoplasm: This could be caused by the fact that L-ASNase prevents several forms of glycosylation, including sialylation, in newly synthesized proteins.38,39 In addition, E. coli L-ASNase possesses glutaminase activity, which results in deprivation of L-glutamine.39 Whereas, bacterial tumor therapy circumvents the systemic injection of high-dose L-ASNase, thereby avoiding systemic toxicity while maintaining sufficient levels inside the tumor tissue.